Trial ID or NCT#



not recruiting iconNOT RECRUITING


SF1126 is a novel inhibitor of PI3 kinase and mTOR that includes an active moiety (consisting of LY294002) linked to an RGDS tetrapeptide that targets the active agent to integrin expressing tissues. In this first pediatric phase 1 trial of SF1126, dose escalation will follow a 3+3 dose escalation design. Once a recommended phase 2 pediatric dose is identified, an expansion cohort of 10 patients with tumors with MYCN amplification, Mycn expression, or Myc expression will be treated.

Official Title

Phase I Study of SF1126 for Patients With Relapsed or Refractory Neuroblastoma

Eligibility Criteria

Ages Eligible for Study: 1 Year to 30 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Contact us to find out if this trial is right for you.


Claire - Twist, MD
(650) 723-5535